Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis

American Journal of Pathology

Volumn 174, Issue 3, 2009, Pages 762-770

  Romagnoli, Solange ^a   Fasoli, Ester ^a   Vaira, Valentina ^a   Falleni, Monica ^a   Pellegrini, Caterina ^a   Catania, Anna ^b   Roncalli, Massimo ^c   Marchetti, Antonio ^d   Santambrogio, Luigi ^a   Coggi, Guido ^a   Bosari, Silvano ^a,e  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

^e Division of Pathology AOS Paolo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN 6; CHECKPOINT KINASE 1; CYCLIN B1; CYCLIN D2; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 2C; CYCLIN H; CYCLINE; DOXORUBICIN; FORKHEAD TRANSCRIPTION FACTOR; PROTEIN FOXM1; PROTEIN UBE1L; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE S PHASE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY;

EID: 62549114849     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080721     Document Type: Article

References (51)

1. Robinson BW, Musk AW, Lake RA: Malignant mesothelioma. Lancet 2005, 366:397-408
2. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70
3. Sherr CJ: Cancer cell cycles. Science 1996, 274:1672-1677
4. Kratzke RA, Otterson GA, Lincoln CE, Ewing S, Oie H, Geradts J, Kaye FJ: Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 1995, 87:1870-1875
5. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, Nobori T, Olopade OI, Buckler AJ, Testa JR: p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994, 54:5547-5551
6. López-Ríos F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, Illei PB, Hussain S, Krug L, Zakowski MF, Rusch V, Olshen AB, Ladanyi M: Global gene expression profiling of pleural mesotheliomas: overexpression of Aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006, 66:2970-2979
7. Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT: Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis 2002, 23:1127-1130
8. Wong L, Zhou J, Anderson D, Kratzke RA: Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer 2002, 38:131-136
9. Ladanyi M: Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer 2005, 49(Suppl 1):S95-S98
10. Borczuk AC, Taub RN, Hesdorffer M, Hibshoosh H, Chabot JA, Keohan ML, Alsberry R, Alexis D, Powell CA: P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res 2005, 11:3303-3308
11. Beer TW, Shepherd P, Pullinger NC: p27 immunostaining is related to prognosis in malignant mesothelioma. Histopathology 2001, 38:535-541
12. Bongiovanni M, Cassoni P, De Giuli P, Viberti L, Cappia S, Ivaldi C, Chiusa L, Bussolati G: p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer 2001, 92:1245-1250
13. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (Eds): World Health Organization Classification of Tumours. Pathology, Genetics, Tumours of the Lung, Pleura, Thymus and Heart. Lyon, IARC Press, 2004 , pp 126-127
14. Catania A, Colombo G, Carlin A, Garofalo L, Gatti S, Buffa R, Carboni N, Rosso L, Santambrogio L, Cantalamessa L, Lipton JM: Autocrine inhibitory influences of alpha-melanocyte-stimulating hormone in malignant pleural mesothelioma. J Leukoc Biol 2004, 75:253-259
15. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3:RESEARCH0034.1-RESEARCH0034.11
16. Barberis M, Pellegrini C, Cannone M, Arizzi C, Coggi G, Bosari S: Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis. Am J Clin Pathol 2008, 129:563-570
17. Pitha-Rowe I, Petty WJ, Feng Q, Koza-Taylor PH, Dimattia DA, Pinder L, Dragnev KH, Memoli N, Memoli V, Turi T, Beebe J, Kitareewan S, Dmitrovsky E: Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Res 2004, 64:8109-8115
18. Zhou BB, Bartek J: Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004, 4:216-225
19. Xiao Z, Xue J, Semizarov D, Sowin TJ, Rosenberg SH, Zhang H: Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimicotics. Int J Cancer 2005, 115:528-538
20. Luo Y, Rockow-Magnone SK, Kroeger PE, Frost L, Chen Z, Han EK, Ng SC, Simmer RL, Giranda VL: Blocking Chk1 expression induces apoptosis and abrogates the G2 checkpoint mechanism. Neoplasia 2001, 3:411-419
21. Chen Z, Xiao Z, Chen J, Ng SC, Sowin T, Sham H, Rosenberg S, Fesik S, Zhang H: Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol Cancer Ther 2003, 2:543-548
22. Manfredi JJ, Dong J, Liu WJ, Resnick-Silverman L, Qiao R, Chahinian P, Saric M, Gibbs AR, Phillips JI, Murray J, Axten CW, Nolan RP, Aaronson SA: Evidence against a role for SV40 in human mesothelioma. Cancer Res 2005, 65:2602-2609
23. Macip S, Kosoy A, Lee SW, O'Connell MJ, Aaronson SA: Oxidative stress induces a prolonged but reversible arrest in p53-null cancer cells, involving a Chk1-dependent G2 checkpoint. Oncogene 2006, 25:6037-6047
24. Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, Clevers H, Medema RH: FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005, 7:126-136
25. Chan D, Yu S, Chiu P, Yao K, Liu V, Cheung A, Ngan H: Overexpression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis. J Pathol 2008, 215:245-252
26. Bektas N, Haaf A, Veeck J, Wild PJ, Luscher-Firzlaff J, Hartmann A, Knuchel R, Dahl E: Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer 2008, 8:42
27. Takeno S, Noguchi T, Kikuchi R, Uchida Y, Yokoyama S, Muller W: Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinoma. Cancer 2002, 94:2874-2881
28. Vivo C, Levy F, Pilatte Y, Fleury-Feith J, Chretien P, Monnet I, Kheuang L, Jaurand MC: Control of cell cycle progression in human mesothelioma cells treated with gamma interferon. Oncogene 2001, 20:1085-1093
29. Kettunen E, Vivo C, Gattacceca F, Knuutila S, Jaurand MC: Gene expression profiles in human mesothelioma cell lines in response to interferon-gamma treatment. Cancer Genet Cytogenet 2004, 152:42-51
30. Sun X, Wei L, Liden J, Hui G, Dahlman-Wright K, Hjerpe A, Dobra K: Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling. J Pathol 2005, 207:91-101
31. Christensen BC, Godleski JJ, Roelofs CR, Longacker JL, Bueno R, Sugarbaker DJ, Marsit CJ, Nelson HH, Kelsey KT: Asbestos burden predicts survival in pleural mesothelioma. Environ Health Perspect 2008, 116:723-726
32. Suzuki M, Toyooka S, Shivapurkar N, Shigematsu H, Miyajima K, Takahashi T, Stastny V, Zern AL, Fujisawa T, Pass HI, Carbone M, Gazdar AF: Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection. Oncogene 2005, 24:1302-1308
33. Zheng N, Fraenkel E, Pabo CO, Pavletich NP: Structural basis of DNA recognition by the heterodimeric cell cycle transcription factor E2F-DP. Genes Dev 1999, 13:666-674
34. Schlecht NF, Burk RD, Adrien L, Dunne A, Kawachi N, Sarta C, Chen Q, Brandwein Gensler M, Prystowsky MB, Childs G, Smith RV, Belbin TJ: Gene expression profiles in HPV-infected head and neck cancer. J Pathol 2007, 213:283-293
35. Slebos RJ, Yi Y, Ely K, Carter J, Evjen A, Zhang X, Shyr Y, Murphy BM, Cmelak AJ, Burkey BB, Netterville JL, Levy S, Yarbrough WG, Chung CH: Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 2006, 12:701-709
36. Reimer D, Sadr S, Wiedemair A, Concin N, Hofstetter G, Marth C, Zeimet AG: Heterogeneous cross-talk of E2F family members is crucially involved in growth modulatory effects of interferon-gamma and EGF. Cancer Biol Ther 2006, 5:771-776
37. Liu CJ, Lin SC, Chen YJ, Chang KM, Chang KW: Array-comparative genomic hybridization to detect genomewide changes in microdissected primary and metastatic oral squamous cell carcinomas. Mol Carcinog 2006, 45:721-731
38. Wang JY: Regulation of cell death by the Abl tyrosine kinase. Oncogene 2000, 19:5643-5650
39. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939
40. Zavadil J, Bottinger EP: TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005, 24:5764-5774
41. Puisieux A, Valsesia-Wittmann S, Ansieau S: A twist for survival and cancer progression. Br J Cancer 2006, 94:13-17
42. Cheng GZ, Zhang W, Wang LH: Regulation of cancer cell survival, migration, and invasion by Twist: AKT2 comes to interplay. Cancer Res 2008, 68:957-960
43. Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, Pottorf BJ, Nitz MD, Richards WG, Sugarbaker DJ, Bueno R: Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 2005, 166:1827-1840
44. Singhal S, Wiewrodt R, Malden LD, Amin KM, Matzie K, Friedberg J, Kucharczuk JC, Litzky LA, Johnson SW, Kaiser LR, Albelda SM: Gene expression profiling of malignant mesothelioma. Clin Cancer Res 2003, 9:3080-3097
45. Schramm A, Vandesompele J, Schulte JH, Dreesmann S, Kaderali L, Brors B, Eils R, Speleman F, Eggert A: Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome. Clin Cancer Res 2007, 13:1459-1465
46. Xiao Z, Xue J, Sowin TJ, Zhang H: Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol Cancer Ther 2006, 5:1935-1943
47. Tse AN, Rendahl KG, Sheikh T, Cheema H, Aardalen K, Embry M, Ma S, Moler EJ, Ni ZJ, Lopes de Menezes DE, Hibner B, Gesner TG, Schwartz GK: CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res 2007, 13:591-602
48. Cho SH, Toouli CD, Fujii GH, Crain C, Parry D: Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle 2005, 4:131-139
49. Edelman MJ, Bauer Jr KS, Wu S, Smith R, Bisacia S, Dancey J: Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. Clin Cancer Res 2007, 13:2667-2674
50. Jimeno A, Rudek MA, Purcell T, Laheru DA, Messersmith WA, Dancey J, Carducci MA, Baker SD, Hidalgo M, Donehower RC: Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother Pharmacol 2008, 61:423-433
51. Perez RP, Lewis LD, Beelen AP, Olszanski AJ, Johnston N, Rhodes CH, Beaulieu B, Ernstoff MS, Eastman A: Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clin Cancer Res 2006, 12:7079-7085